{"id":"NCT03154476","sponsor":"Mayo Clinic","briefTitle":"Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study","officialTitle":"Sildenafil for Fontan Associated Liver Disease (SiFALD) Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-07-05","primaryCompletion":"2019-06-30","completion":"2019-06-30","firstPosted":"2017-05-16","resultsPosted":"2021-07-28","lastUpdate":"2021-08-23"},"enrollment":20,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"OTHER"},"conditions":["Cirrhosis","Congenital Heart Disease"],"interventions":[{"type":"DRUG","name":"Sildenafil","otherNames":["Revatio"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sildenafil","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if the medication, sildenafil (also known as Revatio), can slow or stop the progression of liver disease in patients who previously had a Fontan operation.","primaryOutcome":{"measure":"Liver Stiffness as Measured by Magnetic Resonance Elastography (MRE)","timeFrame":"Baseline, 12 months (52 weeks), 24 months (104 weeks)","effectByArm":[{"arm":"Sildenafil","deltaMin":5.69,"sd":0.73},{"arm":"Placebo","deltaMin":5.72,"sd":0.83}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":12},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["https://www.mayo.edu/research/clinical-trials"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":10},"commonTop":[]}}